Biotech Values

[DewDiligence]

It’s so thoughtful of Sanofi to be concerned for patients…

http://en.sanofi-aventis.com/binaries/20100723_enoxaparine_en_tcm28-28977.pdf

Sanofi-aventis has reservations on today’s approval by the U.S. Food and Drug Administration (FDA) of another version of enoxaparin sodium. As a responsible healthcare company, sanofi-aventis is concerned by potential implications for patient safety, since the product approved today has not been subjected to extensive clinical trials to demonstrate its efficacy and safety as sanofi-aventis has done with its product Lovenox.

SNY’s 2Q10 CC is July 29 at 8:30am ET (2:30pm Paris time). I plan to listen.